– USA CA – Immunicom, Inc., a clinical-stage biotechnology company pioneering a first-of-its-kind technology platform for immuno-oncology, today announced the appointments of Dr. Peter Farrell and Michael E. Lehman to its Board of Directors.
“It is an honor to have Dr. Peter Farrell and Mr. Michael Lehman join Immunicom’s Board of Directors. Their participation is further validation of our planned path. With the addition of these esteemed members, along with our current Board and the remarkable team at Immunicom, the Company is preparing for significant product and financial market events over the next two years.” said founder and CEO, Amir Jafri.
Mr. Lehman, a seasoned corporate leader, brings financial and operational expertise with a focus on IPO readiness, while Dr. Farrell, founder, and Chairman of ResMed, has a proven track record of recognizing and establishing new standards of care for medical innovations.
About Dr. Peter Farrell
Dr. Farrell founded S&P 500 company ResMed in 1989. Under his visionary guidance as CEO and Chairman, his company established the CPAP (Continuous Positive Airway Pressure) medical device as a critical and essential standard of care in the management of cardiovascular health. He remains Chairman and a non-officer employee. He sits on the boards of numerous public and private companies, serves as the MIT Dean of Engineering’s Advisory Council, and on the faculty advisory boards of UC San Diego’s Rady Business School and Jacobs School of Engineering.
“Immunicom has developed a truly novel approach to immuno-oncology called Immunopheresis. It pivots the site of treatment outside the body and is designed to be markedly better tolerated than existing drug immunotherapies,” said Dr. Farrell.
He holds a BE in chemical engineering with honors from the University of Sydney, an SM in chemical engineering from MIT, a Ph.D. in chemical engineering and bioengineering from the University of Washington-Seattle, and a DSc from the University of New South Wales for research contributions in the field of treatment with the artificial kidney.
About Michael E. Lehman
Mr. Lehman has extensive experience as CFO and COO for high-growth companies, with the direct corporate management of key operating functions, including finance, legal, HR, IT, manufacturing operations and supply chain, facilities/real estate, and corporate strategy/development and planning. He was CFO of Sun Microsystems for 13 years over two stints with the company, and CFO and interim CEO of Palo Alto Networks, successfully realizing its operating plan to achieve IPO readiness while growing revenues eight-fold during his tenure. For the last five years, he has served his alma mater, the University of Wisconsin-Madison, as a special advisor to the Chancellor. He is currently the lead independent director and chair of the Management Development, Nominating, and Governance Committee for an NYSE listed company, and Audit Committee Chair for a NASDAQ listed company.
“Immunopheresis is an extremely creative and promising approach to cancer treatment. I have been an investor in the Company since 2019 because of Immunicom’s innovative technology platform, and I am gratified by their near-term results and the potential their products and technologies offer cancer patients,” said Mr. Lehman.
About Immunicom
Immunicom, Inc. is a privately held medical technology company with a new technology platform for immuno-oncology. Immunicom’s blood-filtering Immunopheresis technology is designed to effectively treat a wide variety of cancer types and other terminal diseases with a safer side-effect profile than conventional treatments. Immunicom’s lead product previously received FDA Breakthrough Device designation in 2018 for stage IV metastatic cancer, and European regulatory clearance in 2021 for use in patients with advanced, refractory, triple-negative breast cancer. Immunopheresis is currently being evaluated in several global oncology trials for multiple cancers. Immunicom is headquartered in San Diego, CA, with operations in Houston, TX, Philadelphia, PA, Krakow, Poland, and Istanbul, Turkey.
For more information: https://immunicom.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.